Repercussions of melatonin on the risk of breast cancer: a systematic review and meta-analysis

Imagem de Miniatura
Arquivos
art_VEIGA_Repercussions_of_melatonin_on_the_risk_of_breast_2019.PDF (296.49 KB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2019
Editora
ASSOC MEDICA BRASILEIRA
DOI
Indexadores
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
VALENTI, Vitor E.
CIPOLLA-NETO, Jose
ABREU, Luiz Carlos
BARROS, Ernane Pedro Matos
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.65, n.5, p.699-705, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Breast Cancer is common in women, but its etiology is not yet fully understood. Several factors may contribute to its genesis, such as genetics, lifestyle, and the environment. Melatonin may be involved in the process of breast cancer. Therefore, the aim of this study is to evaluate the influence of the levels of melatonin on breast cancer through a systematic review and meta-analysis. We performed a systematic review according to PRISMA recommendations. The primary databases MEDLINE, Embase, and Cochrane were consulted. There was no restriction on the year of publication and language. Data of systematic reviews from April 2017 to September to 2017 were analyzed. The meta-analysis was conducted using RevMan 5.3 software provided by the Cochrane Collaboration. From a total of 570 articles, 9 manuscripts were included in this review. They analy onzed women with breast cancer and control patients, of which 10% and 90% were in the reproductive period and after menopause, respectively. The lowest level of melatonin was found in approximately 55% of studies with breast cancer in post-menopause. The metanalyses of the studies demonstrated low levels of melatonin in breast cancer patients (n=963) compared with control patients (n=1332), with a mean difference between the studies of -3.54 (CI -6.01, -1.06). Another difference found was in the comparison between smoking patients, with an average difference between 1.80 [0.97-2.63]. Our data suggest that low levels of melatonin might be a risk factor for breast cancer.
Palavras-chave
Melatonin, Breast Neoplasms, Review, Risk factors, Meta-Analysis
URI
https://observatorio.fm.usp.br/handle/OPI/32497
Referências
  1. Ajith Thekkuttuparambil Ananthanarayanan, 2015, J Exp Ther Oncol, V11, P33
  2. BARTSCH C, 1981, J NEURAL TRANSM, V52, P281, DOI 10.1007/BF01256753
  3. BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531
  4. Bernardo Wanderley Marques, 2004, Rev. Assoc. Med. Bras., V50, P104, DOI 10.1590/S0104-42302004000100045
  5. Boyko Y, 2017, NAT SCI SLEEP, V9, P277, DOI 10.2147/NSS.S151525
  6. Brainard GC, 2001, J NEUROSCI, V21, P6405
  7. Brown SB, 2015, AM J EPIDEMIOL, V181, P155, DOI 10.1093/aje/kwu261
  8. Conrad C, 2018, INT J CANCER, V142, P779, DOI 10.1002/ijc.31090
  9. Cos S, 2014, ONCOL LETT, V8, P487, DOI 10.3892/ol.2014.2203
  10. DANFORTH DN, 1985, J CLIN ONCOL, V3, P941, DOI 10.1200/JCO.1985.3.7.941
  11. Devore EE, 2017, CANCER EPIDEM BIOMAR, V26, P413, DOI 10.1158/1055-9965.EPI-16-0630
  12. Erdem JS, 2017, J CANCER, V8, P2876, DOI 10.7150/jca.21064
  13. Erdem JS, 2017, CANCER MED-US, V6, P1988, DOI 10.1002/cam4.1135
  14. Ferrari J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000964.pub3
  15. Ferreira SG, 2013, BRAZ J MED BIOL RES, V46, P278, DOI 10.1590/1414-431X20122230
  16. Gamble KL, 2014, NAT REV ENDOCRINOL, V10, P466, DOI 10.1038/nrendo.2014.78
  17. Gareth ED, 2014, BREAST CANCER RES TR, V145, P663, DOI 10.1007/s10549-014-2931-9
  18. Harpsoe NG, 2015, EUR J CLIN PHARMACOL, V71, P901, DOI 10.1007/s00228-015-1873-4
  19. HOLDAWAY IM, 1991, BRIT J CANCER, V64, P149, DOI 10.1038/bjc.1991.259
  20. Kaunisto A, 2015, MOL ONCOL, V9, P1140, DOI 10.1016/j.molonc.2015.02.004
  21. Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450
  22. Madaeva I M, 2017, Zh Nevrol Psikhiatr Im S S Korsakova, V117, P81, DOI 10.17116/jnevro20171175181-84
  23. Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
  24. Nagata C, 2017, CHRONOBIOL INT, V34, P1187, DOI 10.1080/07420528.2017.1355313
  25. Nooshinfar E, 2016, BIOMED PHARMACOTHER, V83, P456, DOI 10.1016/j.biopha.2016.07.004
  26. Park SY, 2010, J PINEAL RES, V48, P178, DOI 10.1111/j.1600-079X.2009.00742.x
  27. Proietti S, 2013, CELL MOL LIFE SCI, V70, P2139, DOI 10.1007/s00018-012-1161-8
  28. Schernhammer ES, 2005, J NATL CANCER I, V97, P1084, DOI 10.1093/jnci/dji190
  29. Schernhammer ES, 2008, J NATL CANCER I, V100, P898, DOI 10.1093/jnci/djn171
  30. Schernhammer ES, 2010, CANCER EPIDEM BIOMAR, V19, P729, DOI 10.1158/1055-9965.EPI-09-1229
  31. Schernhammer ES, 2009, CANCER EPIDEM BIOMAR, V18, P74, DOI 10.1158/1055-9965.EPI-08-0637
  32. Shin IS, 2015, J PINEAL RES, V58, P50, DOI 10.1111/jpi.12192
  33. Tan DX, 2016, J PINEAL RES, V61, P27, DOI 10.1111/jpi.12336
  34. Varea O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005153
  35. Xu J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05752-9
  36. Zheng JM, 2011, MOL ENDOCRINOL, V25, P2054, DOI 10.1210/me.2011-1141

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03